Aprepitant-loaded solid lipid nanoparticles: a novel approach to enhance oral bioavailability

• Mazhar Hussain,
• Muhammad Farooq,
• Muhammad Asad Saeed,
• Muhammad Ijaz,
• Sherjeel Adnan,
• Zeeshan Masood,
• Muhammad Waqas,
• Wafa Ishaq and
• Nabeela Ameer

Beilstein J. Nanotechnol. 2025, 16, 652–663, doi:10.3762/bjnano.16.50

• , Robert Stevenson Road, Edinburgh, EH9 3FB, United Kingdom 10.3762/bjnano.16.50 Abstract Objectives of the present study are the development of aprepitant (APT)-loaded solid lipid nanoparticles (SLNs) using the polymers poloxamer 407 and β-cyclodextrin for enhanced solubility and their pharmacokinetic

• . Therefore, the optimal SLN formulation APT-CD-NP4 is a promising tool for oral administration with sustained release to improve the bioavailability of the BCS class-IV drug APT. Keywords: aprepitant; β-cyclodextrin; pharmacokinetic study; poloxamer; solid lipid nanoparticles; Introduction Cancer is a

• patients in the delayed phase (days 2 to 5) in their first cycle of high-dose cisplatin [5]. Aprepitant (APT) is a selective antagonist of neurokinin-1 receptor that blocks the substance P emetic effect. NK-1 receptors occur in the gastrointestinal tract on vagal afferents and in the nucleus of the

Preservation of rutin nanosuspensions without the use of preservatives

• Pascal L. Stahr and
• Cornelia M. Keck

Beilstein J. Nanotechnol. 2019, 10, 1902–1913, doi:10.3762/bjnano.10.185

• ® (Sirolimus, Wyeth), Emend® (Aprepitant, Merck), Tricor® (Fenofibrate, Abbott), Megace ES® (Megestrol, Par Pharm) or Triglide® (First Horizon Pharmaceuticals). In 2009 the first parenteral drug product, Invega Sustenna® (Paliperidone palmitate, Johnson & Johnson), was approved by the FDA. However, besides